Article
Acquired BRAF N581S mutation mediated resistance to gefitinib and responded to dabrafenib plus trametinib.
Lung cancer (Amsterdam, Netherlands) - 1 Aug 2020
Liu Yujie, Zeng Hao, Wang Ke, Li Yalun, Tian Panwen, Li Weimin
Abstract excerpt
OBJECTIVES: BRAFG469A and V600E were reported as the mechanisms of acquired resistance to first-generation EGFR tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer patients. Here, we described a rare case of BRAF N581S after gefitinib resistance and response to BRAF inhibitor plus MEK inhibitor. MATERIALS AND METHODS: Next-generation sequencing (NGS) was performed on the tumor tissue and plasma...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.